Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

1.3K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.3K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.3K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.3K
Clinical Trials: Overview01:11

Clinical Trials: Overview

5.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neoadjuvant endocrine therapy with or without palbociclib in low-risk patients: a phase III randomized double-blind SAFIA trial.

Journal of cancer research and clinical oncology·2023
Same author

Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

Patterns of cardiovascular risk and disease in HIV-positive adults on anti-retroviral therapy in Mozambique.

Cardiovascular journal of Africa·2020
Same author

Retraction notice to "Nipple adenoma in a man: An unusual case report" [Int. J. Surg. Case Rep. 3 (2012) 190-192].

International journal of surgery case reports·2018
Same author

Evolution of quality of life in patients with breast cancer during the first year of follow-up in Morocco.

BMC cancer·2018
Same author

[Meningeal carcinomatosis in breast cancer: from diagnosis to treatment].

Revista de neurologia·2017

Related Experiment Video

Updated: Mar 31, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

28.0K

Bevacizumab in clinical practice.

N Majid1, I Ghissassi1, H Mrabti1

  • 1Department of Medical Oncology, National Institute of Oncology, Rabat, Morocco.

The Gulf Journal of Oncology
|October 27, 2015
PubMed
Summary
This summary is machine-generated.

Bevacizumab, an angiogenesis inhibitor, is effective for solid tumors but requires monitoring for adverse effects like hypertension and hemorrhage. Understanding its toxicity profile improves patient outcomes and therapy duration.

More Related Videos

Cerenkov Luminescence Imaging CLI for Cancer Therapy Monitoring
08:45

Cerenkov Luminescence Imaging CLI for Cancer Therapy Monitoring

Published on: November 13, 2012

14.4K
Three-dimensional Angiogenesis Assay System using Co-culture Spheroids Formed by Endothelial Colony Forming Cells and Mesenchymal Stem Cells
09:24

Three-dimensional Angiogenesis Assay System using Co-culture Spheroids Formed by Endothelial Colony Forming Cells and Mesenchymal Stem Cells

Published on: September 18, 2019

10.8K

Related Experiment Videos

Last Updated: Mar 31, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

28.0K
Cerenkov Luminescence Imaging CLI for Cancer Therapy Monitoring
08:45

Cerenkov Luminescence Imaging CLI for Cancer Therapy Monitoring

Published on: November 13, 2012

14.4K
Three-dimensional Angiogenesis Assay System using Co-culture Spheroids Formed by Endothelial Colony Forming Cells and Mesenchymal Stem Cells
09:24

Three-dimensional Angiogenesis Assay System using Co-culture Spheroids Formed by Endothelial Colony Forming Cells and Mesenchymal Stem Cells

Published on: September 18, 2019

10.8K

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Targeted cancer therapies, including angiogenesis inhibitors, represent a significant advancement.
  • Bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor (VEGF), is approved for various solid tumors.

Purpose of the Study:

  • To review the side effects of bevacizumab observed in clinical trials.
  • To outline guidelines for managing bevacizumab-associated adverse events.

Main Methods:

  • Review of clinical trial data for bevacizumab.
  • Analysis of published guidelines for adverse event management.

Main Results:

  • Bevacizumab is generally well-tolerated.
  • Key adverse events requiring monitoring include vascular and renal toxicities such as hypertension, proteinuria, thromboembolic events, and hemorrhage.

Conclusions:

  • Optimal management of bevacizumab toxicity is crucial for patient safety.
  • Patient education and adherence to management guidelines can facilitate prolonged therapy and improve clinical outcomes.